Francoise Solly

Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Cytotoxic CD4+ T cells induce age-associated myelopoiesis through CCL5-CCR5 signaling.

Cytotoxic CD4+ T cells induce age-associated myelopoiesis through CCL5-CCR5 signaling.

Journal: Nature aging
Published: May 22, 2026

Cryptic KMT2A::MLLT10 Rearrangement in a Highly Aggressive Acute Myeloid Leukemia.

Cryptic KMT2A::MLLT10 Rearrangement in a Highly Aggressive Acute Myeloid Leukemia.

Journal: International journal of laboratory hematology
Published: September 17, 2024

Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.

Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 19, 2024

A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications.

A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications.

Journal: International journal of molecular sciences
Published: June 26, 2024

Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript.

Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript.

Journal: Annals of hematology
Published: May 12, 2023

Vorinostat for treatment-refractory bullous pemphigoid.

Vorinostat for treatment-refractory bullous pemphigoid.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 17, 2023

Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.

Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.

Journal: Hematology (Amsterdam, Netherlands)
Published: February 23, 2023

Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.

Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.

Journal: Biomarker research
Published: October 08, 2021

Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.

Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.

Journal: American journal of hematology
Published: October 04, 2021

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Journal: Blood advances
Published: July 12, 2019

Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.

Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology
Published: December 27, 2018

Over 20 years of treatment-free remission after interferon-alpha monotherapy for chronic myeloid leukemia.

Over 20 years of treatment-free remission after interferon-alpha monotherapy for chronic myeloid leukemia.

Journal: Leukemia research
Published: August 14, 2018
Showing 1-12 of 25

Last Updated: 09/26/2026